RBBP8表达在浆细胞骨髓瘤中的预后价值
Prognosis value of RBBP8 expression in plasma cell myeloma
原文发布日期：2019-01-09
英文摘要：
摘要翻译：
原文链接：
Plasma cell myeloma (PCM) secretes monoclonal immunoglobulin (Ig) by clonal plasma cells of abnormal proliferation in the bone marrow. As PCM is incurable, it is necessary to find new biomarkers to predict the prognosis and recurrence of PCM. The relationship between cancer and RBBP8 has not been fully studied. The role of RBBP8 in tumorigenesis remains inconsistent. We described the expression of RBBP8 in the gene expression profile of 1930 PCM samples (1878 PCM patients) from seven independent data sets. We analyzed the relationship between RBBP8 and survival prognosis, recurrence, and treatment response in patients with PCM, and the biological significance of RBBP8 in PCM. The gene expression level of RBBP8 was significantly related to the International staging system (ISS) grade of PCM (P = 0.0012). RBBP8 expression in different molecular subtypes was different (P < 2.2e-16). High RBBP8 expression is associated with poor survival in PCM (P < 0.0001). High expression of RBBP8 indicates that PCM patients are more likely to relapse (P = 0.0078). The biological significance of RBBP8 in PCM is related to the cell cycle (P < 0.05). High RBBP8 expression predicts poorer survival and more likely relapse in PCM. RBBP8 plays an important role in the cell cycle of PCM. RBBP8 can be considered an independent prognostic factor for PCM. RBBP8 can be used as a potential biomarker for assessing the prognosis of PCM patients.
浆细胞骨髓瘤（PCM）是由骨髓中异常增殖的克隆性浆细胞分泌单克隆免疫球蛋白（Ig）的恶性肿瘤。由于PCM目前无法治愈，需要寻找新的生物标志物来预测其预后和复发风险。RBBP8与癌症的关系尚未得到充分研究，其在肿瘤发生中的作用仍存在争议。本研究基于七个独立数据集中1930例PCM样本（来自1878例患者）的基因表达谱，描述了RBBP8的表达特征，分析了RBBP8与PCM患者生存预后、复发及治疗反应的关系，并探讨了RBBP8在PCM中的生物学意义。结果显示：RBBP8基因表达水平与国际分期系统（ISS）分级显著相关（P=0.0012）；不同分子亚型中RBBP8表达存在差异（P<2.2e-16）；高RBBP8表达与不良生存预后相关（P<0.0001），且提示患者更易复发（P=0.0078）；RBBP8在PCM中的生物学功能主要与细胞周期相关（P<0.05）。结论表明：RBBP8高表达预示PCM患者生存期更短、复发风险更高；该基因通过调控细胞周期在PCM中发挥重要作用，可作为独立的预后评估因子，并有望成为评估PCM患者预后的潜在生物标志物。
……
肿瘤(癌症)患者之家